Life sciences companies are not short on AI ambition. Pharma, biotech, and medtech firms have poured billions into generative AI, machine learning platforms, and now agentic systems, and the appetite shows no sign of slowing. But if you ask how much of that investment has actually changed how work gets done, the answer gets a lot quieter. AI for life sciences has become a story of two speeds: fast adoption and slow, uneven return.
That gap is not a technology problem. It’s a workflow problem, and it shows up in the data.
The Investment Is Real, and So Is the Gap
Deloitte’s 2026 Life Sciences Outlook Survey, which polled 280 C-suite executives across biopharma and medtech companies in the US, Europe, and Asia, found that nearly half of respondents identified accelerated digital transformation and AI as a trend likely to have a substantial impact on their organization this year. Despite these investments, only 22% of life sciences leaders said they have successfully scaled AI.
That’s not a small miss. It’s a pattern. A separate ZS Associates and Harris Poll survey of technology executives at pharmaceutical and biotech companies found that only 40% of AI pilots reach scaled deployment, and just 17% of respondents say they can already prove measurable value from AI in discovery work. The story repeats itself across industries too. MIT’s Project NANDA studied more than 300 enterprise generative AI deployments and found that 95% delivered no measurable impact on profit and loss, even though only 5% of integrated systems created significant value. Life sciences isn’t an outlier here. It’s a case study in a much broader trend. Legal.io
None of this means the tools don’t work. Protein-folding models, literature-review assistants, and clinical documentation copilots have all proven genuinely useful in narrow, well-defined tasks. The problem is what happens after the pilot. Most organizations bolt AI onto an existing process and expect the process to bend around it. It usually doesn’t.
Why Tool-First Thinking Fails in Regulated Environments
Life sciences has a structural disadvantage that makes this problem worse than in most industries: everything runs through validation, documentation, and audit trails. A generic AI rollout that works fine in marketing or customer support runs into a different reality in clinical operations, regulatory affairs, or pharmacovigilance, where every output needs a paper trail and every process change needs sign-off from compliance.
Picture a mid-size specialty pharma company’s regulatory affairs team. They adopt a generative AI tool to help draft sections of clinical study reports and speed up literature reviews. The tool works. Drafts come back faster. But the approval workflow around those drafts hasn’t changed. Reviewers still route documents the same way, through the same number of sign-offs, on the same timeline they used before AI existed. The bottleneck was never how fast a first draft got written. It was how the document moved through the organization afterward. Six months later, the team has a faster first step and the same overall cycle time, because nobody redesigned the steps that came after it.
This is the pattern behind that Deloitte 22% figure and the MIT findings both. Companies buy capability without rebuilding the operating system it needs to run inside. The tool changes. The workflow around it doesn’t. And leadership ends up asking why an expensive AI investment produced no measurable change in throughput, cost, or time to market.
What Workflow Redesign Actually Looks Like
Getting real value from AI for life sciences means starting with the operating model, not the model itself. That’s the thinking behind our BRAVE framework, which we built specifically to help operations leaders map where AI fits into a workflow before they buy or deploy anything.
In practice, that means asking different questions before rollout. Which specific decision points in this process are actually the bottleneck? Who signs off, and does that approval step need to move earlier or later once AI accelerates the work before it? What data does the AI tool need to see, and does anyone actually own the job of keeping that data clean and current? These aren’t exciting questions. They’re also the ones that separate the 22% who scale AI successfully from the majority stuck running pilots on repeat.
Organizations that get this right tend to redesign in sequence rather than all at once. They pick one workflow, usually one with clear volume and a measurable outcome, like adverse event triage, protocol amendment review, or medical information request handling. They map the current process end to end, including the parts nobody likes to admit are manual and slow. Then they rebuild the workflow around where AI adds the most leverage, not just where it’s easiest to bolt on.
A Harvard Business Review analysis of enterprise AI adoption makes a related point: the organizations that see real gains from AI are the ones that redesign roles and processes around the technology, not the ones that simply hand existing tasks to a new tool. That’s true in life sciences too, and arguably more true, given how much regulatory structure sits on top of every process.
Starting Where the Data Actually Points
The good news is that life sciences companies don’t need to guess where to start. Benchling’s 2026 Biotech AI Report found that the use cases with the highest adoption rates, like literature review and knowledge extraction, protein structure prediction, and scientific reporting, are exactly the ones with clean, verifiable data behind them. Adoption drops sharply in areas with messier, less structured inputs. That’s not a coincidence. It’s a map. The workflows worth redesigning first are the ones where the underlying data already supports it.
Boards and investors are increasingly asking harder questions about AI spend than they were two years ago. They’re less interested in how many pilots got launched and more interested in what those pilots produced. For life sciences leaders, the honest answer to that question depends less on which AI vendor gets picked and more on whether anyone rebuilt the workflow the tool has to operate inside.
That’s the work we do at StrataBlue. We don’t start with a tool recommendation. We start by mapping how work actually moves through your organization, then figure out where AI genuinely changes the equation versus where it’s just adding another interface to an already broken process. If your organization has invested in AI and isn’t seeing it show up in cycle times, cost, or throughput, that gap is usually fixable. Get your free diagnostic and we’ll show you exactly where the workflow, not the technology, is holding you back.
